|By Marketwired .||
|May 2, 2014 06:30 AM EDT||
WINNIPEG, MANITOBA -- (Marketwired) -- 05/02/14 -- Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces that the Company continues to advance discussions towards finalizing an agreement (the "Agreement") that would see the Scout DS® test distributed exclusively in China by Cachet Pharmaceutical Co., Ltd. ("Cachet").
"I recently completed meetings in Beijing with Cachet's senior executive management team and our Shanghai-based legal counsel. I am pleased to report that the parties have significantly advanced discussions towards the finalization of the Agreement and signing of all definitive documentation," said Christopher J. Moreau, President and CEO of Miraculins Inc.
The completion of the Agreement and execution of definitive documentation remain subject to all necessary contractual, regulatory and corporate approvals of both Miraculins and Cachet and the completion of satisfactory due diligence. There is no assurance that the parties will enter into the Agreement or execute the definitive documentation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements include statements regarding the completion of definitive documentation and the execution of the Agreement. These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statements.
Scout DS® is a registered trademark of Miraculins Inc. All Rights Reserved. 2014.
Aug. 30, 2015 06:45 PM EDT Reads: 362
Aug. 30, 2015 05:00 PM EDT Reads: 126
Aug. 30, 2015 05:00 PM EDT Reads: 457
Aug. 30, 2015 04:00 PM EDT Reads: 146
Aug. 30, 2015 01:30 PM EDT Reads: 214
Aug. 30, 2015 01:30 PM EDT Reads: 181
Aug. 30, 2015 01:00 PM EDT Reads: 276
Aug. 30, 2015 12:00 PM EDT Reads: 263
Aug. 30, 2015 11:00 AM EDT Reads: 169
Aug. 30, 2015 10:30 AM EDT Reads: 431
Aug. 30, 2015 10:30 AM EDT Reads: 871
Aug. 30, 2015 10:15 AM EDT Reads: 220
Aug. 30, 2015 10:00 AM EDT Reads: 337
Aug. 30, 2015 10:00 AM EDT Reads: 225
Aug. 30, 2015 09:45 AM EDT Reads: 190